Author

H. S. Bouzidi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:virus· 2 Assay:metagenomics· 1

Frequent Co-Authors

F. Touret· 2 shared X. de Lamballerie· 2 shared A. Nougairede· 1 shared C. Baronti· 1 shared C. E. Mowbray· 1 shared E. Chatelain· 1 shared F. Escudie· 1 shared G. Piorkowski· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

F. Touret

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

H. S. Bouzidi, J.-S. Driouich, R. Klitting, O. Bernadin, G. Piorkowski, R. Amaral, L. Fraisse, C. E. Mowbray, I. Scandale, F. Escudie, E. Chatelain, X. de Lamballerie, A. Nougairede, F. Touret

The paper generates and evaluates SARS-CoV-2 mutants resistant to protease inhibitors nirmatrelvir and ensitrelvir, showing in vitro and in vivo resistance and linking M49L mutation prevalence to Xocova(R) use.

bioRxiv · Nov 22, 2023Microbiology

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate

F. Touret, C. Baronti, H. S. Bouzidi, X. de Lamballerie

The paper evaluates the neutralizing activity of eight therapeutic antibodies against an Omicron SARS-CoV-2 isolate and finds significant loss of efficacy for most, with only Sotrovimab showing minimal reduction.

bioRxiv · Jan 1, 2022Microbiology